Anti-PD-1/PD-L1 antibodies are monoclonal antibodies selectively targeting the PD-1/PD-L1 pathway and the mechanism of action of ICIs is thought to restore a lost antitumor immunity in the tumor microenvironment [7]. Here, PDCD1 is linked to neoplasm.